Xilio Therapeutics (XLO) News
NASDAQ: XLOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
7.56-0.085 (-1.11%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
XLO news summary
We found 3 recent headlines mentioning Xilio Therapeutics (XLO): 0 in the past week and 3 in the past 30 days, most often from GlobeNewswire. For price context, XLO is down 1.11% at $7.56. The most recent story, "Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business Updates", was published by GlobeNewswire on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Xilio Therapeutics headlines
- Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business UpdatesDosed first patient in Phase 1/2 clinical trial for XTX501, a potential best-in-class PD-1/masked IL-2 bispecific, for patients with metastatic NSCLC, and plan to report initial Phase 1 data in the…GlobeNewswire
- Xilio Therapeutics to Present at the Stifel 2026 Healthcare ConferenceWALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people…GlobeNewswire
- Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLCXTX501 is a novel PD-1/masked IL-2 bispecific that has the potential to become a foundational backbone regimen for solid tumorsGlobeNewswire